Argent BioPharma Limited (RGT.AX) Stock
Argent BioPharma Limited

Company profile
About Argent BioPharma Limited
Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and the United Kingdom. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnicann for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound management. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
Largest shareholders
- Roby Zomer5.934 %5.93%
Share of the company, as of May 19, 2026
Leadership
- Roby Reuven Zomer — Co-Founder, CEO & Chairman, 45
- Amir Polak — Chief Pharmaceutical Development Officer
- Nadya Lisovoder — Chief Medical Officer
- Yair Tal — Chief Information Security Officer
- Andrew Chapman B.Bus(Econ), DFP, GradDipAppFin — Non Executive Director, 50
What companies are similar to Argent BioPharma?
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Mayne Pharma Group Limited (MYX.AX), BTC Health Limited (BTC.AX), Acrux Limited (ACR.AX).
Company Information
Data as of .
How to cite: DataPorium, “Argent BioPharma Limited (RGT.AX)”, data as of May 19, 2026, https://dataporium.tech/stocks/RGT.AX